

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



Date: 9th May, 2025

**To,
National Stock Exchange of India – Emerge Platform
Mumbai**

Scrip Code: ARVEE

ISIN : INE006Z01016

Sub: Outcome of Board Meeting held on 9th May, 2025

Pursuant to our intimation dated 2nd May, 2025 and with reference to Regulation 30, 33 and other applicable regulation, if any, of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we would like to inform that the meeting of the Board of Directors held today on 9th May, 2025 have interalia amongst others approved the following items :

1. Approved the financial results for the quarter and year ended on 31st March, 2025
2. Approved the declaration of unmodified opinion
3. Noted the Auditors Report for the year ended on 31st March, 2025
4. Approved the Statement of Related Party Transaction for the half year ended on 31st March, 2025.
5. Re-appointed Internal Auditors of the Company. The requisite details pursuant to Regulation 30 is annexed herewith.
6. Appointment of M/s. Jalan Alkesh & Associates, Practicing Company Secretaries, (Certificate of Practice : 4580) as Secretarial Auditor of the Company, with effect from April 1, 2025, for a period of 5 years and fix their remuneration, subject to the approval of the members at the ensuing Annual General Meeting of the Company. The requisite details pursuant to Regulation 30 is annexed herewith.

The Board Meeting started at 15:00 Hours and concluded at 16:30 Hours.

Kindly take the above information on record.

Thanking You,

For, Arvee Laboratories (India) Limited

**Whole Time Director
Shalin Bharatbhai Chokshi
DIN: 00191903**



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.

**Annexure to Point No. 5**

Sr. No.	Particulars	Remarks
1	Name and Address of the Firm	M/s Keval Ponkiya & Associates Proprietor : Mr. Keval N. Ponkiya Address : 307, Abhijyot Square, Bh. Divya Bhaskar, S G Highway, Ahmedabad - 380051
2	Date of Re-appointment & Term of Appointment	For FY 2025- 26 and thereafter unless resolved otherwise, to conduct internal audit of the company and shall continue thereafter unless resolved otherwise.
3	Brief Profile	The firm has grown in the areas not only in Statutory Audit, Tax Audit, Internal Audit & Management Consultancy but also in the areas of international Taxation, Foreign and Local Company Formation, Project Finance, Capital Fund Raising, Business Valuation, Takeover, Amalgamation, Merger & Acquisition, Corporate Compliances, SEBI Regulation Compliances, Stock Exchange Compliances, Labour Law Compliances, and liasioning Work with various Government and semi government authorities.
4	Disclosure of relationships between directors (in case of appointment of a director)	Nil

Annexure to Point No. 6

Sr. No.	Particulars	Remarks
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Jalan Alkesh & Associates, Practicing Company Secretaries, as Secretarial Auditor of the Company, with effect from April 1, 2025, for a period of 5 years.
2	Date of Re-appointment & Term of Appointment	The appointment is for a period of 5 (five) consecutive years. The Secretarial Auditor shall conduct the Secretarial Audit for the financial year ending March 31, 2026 to March 31, 2030.
3	Brief Profile	Jalan Alkesh and Associates is a peer reviewed proprietorship firm established in 2002. The firm aims to provide corporate, secretarial, legal,



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



		<p>compliance and management services to clients, using the best tools and technologies, to enable them to deliver and sustain the best compliance management and product/service deliveries in time. They also focus on developing high professional values, ensuring good corporate governance and contributing to public good through proactive research and development activities.</p> <p>The firm is led by Mr. Alkesh Jalan, a Fellow Member of the Institute of Company Secretaries of India, with over 23 years of work experience as a Professional in Practice.</p> <p>The firm has in-depth experience in various areas of practice, including corporate laws, IPO, FPO, Listing, De-listing of Equity Shares, Listing Compliances, Secretarial Management guidance & Audit, Due Diligence, Compliance Audit, Corporate Governance Audit, Merger-Acquisition, and Corporate Restructuring, FEMA, RBI, and other Economic Laws. The firm's office is located in Ahmedabad.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Nil

For, Arvee Laboratories (India) Limited

Whole Time Director
Shalin Bharatbhai Chokshi
DIN: 00191903



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
 403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
 Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
 Phone: +91- 2717-430479 | +91- 2717-410819
 e-mail: info@arveelabs.com, Website: www.arveelabs.com
 CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED****CIN: L24231GJ2012PLC068778**

**Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,
 Iskcon Bopal Road, Ambli, Ahmedabad - 380058**

Tel : +91 – 2717-430479 || +91 – 2717-410819

Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31,2025

(₹ in Lakhs)

Particulars	As at 31/03/2025	As at 31/03/2024
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a)Property Plant and Equipment	1,527.04	1,266.81
(b)Capital Work-in-Progress	72.51	262.47
(c)Other Intangible assets	0.23	0.23
(d)Financial Assets		
(i)Investments	-	-
(ii)Loans	-	-
(iii)Others Financial Assets	25.43	22.44
(e)Deferred tax assets (Net)	-	-
(f)Non-current Assets (Net)	-	-
(g)Other Non-current assets	10.92	34.52
Sub - Total - Non Current Assets	1,636.12	1,586.47
2. Current assets		
(a)Inventories	455.43	639.53
(b)Financial Assets		
(i)Investments	-	-
(ii)Trade receivables		
Billed	839.77	611.28
Unbilled	-	-
(iii)Cash and cash equivalents	21.10	185.01
(iv)Other Bank Balances	576.36	569.00
(v)Others Financial Assets	-	-
(c)Current assets (net)	-	-
(d)Other current assets	287.04	264.99
Sub - Total - Current Assets	2,179.71	2,269.80
TOTAL - ASSETS	3,815.83	3,856.28



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
 403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
 Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
 Phone: +91- 2717-430479 | +91- 2717-410819
 e-mail: info@arveelabs.com, Website: www.arveelabs.com
 CIN No. :- L24231GJ2012PLC068778.



B. EQUITY AND LIABILITIES		
1. Equity		
(a)Equity Share Capital	1,102.00	1,102.00
(b)Other Equity	2,024.13	1,809.40
Sub - Total - Equity	3,126.13	2,911.40
2. LIABILITIES		
Non-current liabilities		
(a)Financial Liabilities		
(i)Borrowings	103.33	100.00
(ii)Others Financial Liabilities	-	-
(b)Other non - current liabilities	29.00	29.98
(c)Provisions	-	-
(d)Deferred tax liabilities (Net)	98.20	84.25
Sub - Total - Non - Current Liabilities	230.53	214.22
Current liabilities		
(a)Financial Liabilities		
(i)Borrowings	-	-
(ii)Trade Payables	327.28	662.32
Total outstanding due of		
(A) Micro enterprises and small enterprises	41.15	42.82
(B) Creditors other than micro enterprises and small enterprises	286.13	619.49
(iii)Other Financial Liabilities		
(b)Other current liabilities	30.55	28.53
(c)Provisions	101.33	39.81
(d)Current Tax Liabilities (Net)	-	-
Sub Total - Current Liabilities	459.16	730.65
TOTAL EQUITY AND LIABILITIES	3,815.83	3,856.28

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN BHARATBHAI CHOKSHI
 WHOLE TIME DIRECTOR
 DIN: 00191903



Date: May 09, 2025
 Place: Ahmedabad

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.


Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



ARVEE LABORATORIES (INDIA) LIMITED CIN: L24231GJ2012PLC068778 Registered Office: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad - 380058 Tel : +91 – 2717-430479 +91 – 2717-410819; Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com					
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED ON MARCH 31, 2025					
(₹ in Lakhs, except per share data)					
Sr. No	Particulars	Quarter Ended			Year Ended
		31/03/2025	31/12/2024	31/03/2024	31/03/2025
		Audited	Unaudited	Audited	Audited
1	Revenue from operations	645.00	890.89	614.35	3,848.72
2	Other income	20.81	18.71	20.68	65.73
3	Total Income (1+2)	665.80	909.61	635.03	3,914.45
4	Expenses				
	Cost of materials consumed	254.72	629.12	522.98	1,887.29
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(24.40)	(105.00)	(312.24)	180.74
	Employee benefits expense	114.91	116.51	110.06	449.47
	Finance costs	6.99	5.34	5.19	24.87
	Depreciation and amortization expense	26.83	27.51	37.30	114.88
	Other expenses	277.39	215.46	213.84	970.10
	Total expenses (4)	656.43	888.93	577.13	3,627.36
5	Profit/(loss) before exceptional items and tax (1-4)	9.37	20.68	57.90	287.09
6	Exceptional Items	-	-	-	-
7	Profit/(loss) before tax (5-6)	9.37	20.68	57.90	287.09
8	Tax expense:				
	Current tax	(11.50)	5.20	11.65	58.40
	Deferred tax	13.96	-	34.64	13.96
9	Profit (Loss) for the period from continuing operations (7-8)	6.92	15.48	11.60	214.74
10	Profit/(loss) from discontinued operations	-	-	-	-
11	Tax expense of discontinued operations	-	-	-	-
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	-	-	-	-
13	Profit/(loss) for the period (9+12)	6.92	15.48	11.60	214.74
14	Other Comprehensive Income				
A	i. Items that will not be reclassified to profit or loss	-	-	-	-
	ii. Income tax relating to items that will not be reclassified to profit & Loss account	-	-	-	-
B	i. Items that will be reclassified to profit or loss	-	-	-	-
	b. Income tax relating to items that will be reclassified to profit & Loss account	-	-	-	-
15	Total Comprehensive Income for the period (13+14)	6.92	15.48	11.60	214.74
	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	1,102.00	1,102.00	1,102.00	1,102.00
16	Earnings per equity share (for continuing operation):				
	Basic	0.06	0.14	0.11	1.95
	Diluted	0.06	0.14	0.11	1.95
17	Earnings per equity share (for discontinued operation):				
	Basic	-	-	-	-
	Diluted	-	-	-	-
18	Earnings per equity share (for continuing & discontinued operation):				
	Basic	0.06	0.14	0.11	1.95
	Diluted	0.06	0.14	0.11	1.95



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



Paid-up equity share capital (Face value of ₹ 10 each)	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00
Other Equity excluding Revaluation Reserve	2,024.13	2,017.22	1,809.40	2,024.13	1,809.40

Notes:

- 1 The aforesaid Financial Results for the quarter ended March 31, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on Friday, May 09, 2025.
- 2 The aforesaid Financial Results for the quarter ended March 31, 2025 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the group fall under the Chemicals business which is considered to be the only reportable segment by the management.
- 4 The figures for the quarter ended on 31st March, 2025 represent the deprived figures between the audited figures in respect of the current full financial year ended 31st March, 2025 and the published year to date revised figures upto 31st December, 2024 being the date of end of 3rd quarter of the current financial year.
- 5 The Company hereby declares that the Auditors have issued unqualified modified opinion in respect of the Audit Report for the financial statements.
- 6 Consolidated financial statements are not applicable.
- 7 We confirm that we are not a Large Corporate as per the applicability criteria given under SEBI Circular SEBI / HO / DDHS / CIR / P / 2018 / 144 dated 26th November, 2018.
- 8 The figures for the corresponding previous period have been restated / regrouped wherever necessary, to make them comparable.
- 9 The Company does not have any Subsidiary/Associate/Joint Venture with any party.

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN BHARATBHAI CHOKSHI
WHOLE TIME DIRECTOR
DIN: 00191903
Date: May 09, 2025
Place: Ahmedabad



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
 403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
 Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
 Phone: +91- 2717-430479 | +91- 2717-410819
 e-mail: info@arveelabs.com, Website: www.arveelabs.com
 CIN No. :- L24231GJ2012PLC068778.



ARVEE LABORATORIES (INDIA) LIMITED				
CIN: L24231GJ2012PLC068778				
Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,				
Iskcon Bopal Road, Ambli, Ahmedabad - 380058				
Tel : +91 – 2717-430479 +91 – 2717-410819; Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com				
AUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2025				
(Amount in Lacs)				
Particulars	2024-25		2023-24	
A: Cash from Operating Activities :				
Net Profit before Taxation		287.08		186.46
Adjustment For :				
Re-measurement gain / (loss) on defined benefit plans				
Depreciation	114.88		149.82	
Amortisation	0.13		0.13	
Prior Period Expenses / (Income)			-	
Loss / (Profit) on Sale of Assets	0.09		-	
Loss / (Profit) on Sale of Investments	(13.46)		(6.49)	
Finance Costs recognised in Statement of Profit and Loss	24.68		24.99	
Excess/Short Provision of Income Tax			-	
Interest Income recognised in Statement of Profit and Loss	(40.31)		(35.81)	
Dividend Income				
		86.01		132.63
Operating Profit Before Working Capital changes :		373.09		319.09
Adjustment For :				
Inventory	184.09		(182.69)	
Trade Receivables	(228.60)		614.85	
Long Term Loans and Advances	(22.18)		71.07	
Other Current Assets	(2.98)		4.56	
Trade Payables	(311.43)		(129.21)	
Other Current Liability	4.27		1.36	
		(376.82)		379.94
Cash Generated From Operations		(3.73)		699.03
Income Tax Paid				(28.24)
Cash from Operating Activity		(3.73)		670.79
B: Cash Flow From Investment Activities :				
Purchase of Fixed Assets	(185.36)		(258.59)	
Sale of Fixed Assets	0.12		-	
Purchase/Sale of Investments	(7.36)		(298.25)	
Profit on sale of Investment	13.46		6.49	
Interest Received	40.31		35.81	
Net Cash from Investment Activities		(138.83)		(514.54)
C: Cash Flow From Financing Activities :				
Proceeds from Issue of Equity Capital				
Share Application Money Received				
Repayment of Long Term Borrowings				
Proceeds From Short Term Borrowings (Net)	3.33		0	
Finance Cost Paid	(24.68)		(24.99)	
Net Cash from Financing Activities		(21.35)		(24.99)



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



Net Increase in Cash & Cash Equivalents (A+B+C)		(163.90)		131.26
Cash & Cash Equivalents at the Beginning of period		185.01		53.75
Cash & Cash Equivalents at the End		21.11		185.01

Date: May 09, 2025
Place: Ahmedabad



For and on behalf of the Board of Directors of
Arvee Laboratories (India) Limited

Shalin Bharatbhai Chokshi
Whole Time Director
[DIN: 00191903]



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



**Declaration of Audited Financial Results of Arvee Laboratories (India) Limited (Standalone)
with Unmodified Opinion for the 4th Quarter and Financial Year ended on 31st March, 2025**

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we, hereby declare that M/s. Nirav Patel & Associates, Statutory auditors of the Company have issued the Audit Reports with unmodified opinions on the Audited Standalone Financial results of the Company for the quarter and year ended March 31, 2025.

For, Arvee Laboratories (India) Limited

SHALIN BHARATBHAJ CHOKSHI
Director
DIN: 00191903



SAURIN GANDHI
Chief Financial Officer



**For, Nirav Patel & Associates
Chartered Accountants
(Firm's Registration No. 129824W)**

Nirav Patel
Partner
(Membership No. 132409)



**To the Board of Directors of
Arvee Laboratories (India) Limited**

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of ARVEE Laboratories (India) Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results. Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results. These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards

prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of



financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

– Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.

– Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

– Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

a. The standalone annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Date: 09/05/2025
Place: Ahmedabad

For, Nirav Patel & Associates
Chartered Accountants
(Firm's Registration No. 129824W)


Nirav Patel
Partner
(Membership No. 132409)
UDIN: 25132409BMLKPF6044

